Singapore Eye Research Institute, Singapore National Eye Center, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore.
Asia Pac J Ophthalmol (Phila). 2021;10(3):299-306. doi: 10.1097/APO.0000000000000400.
Artificial Intelligence (AI), in particular deep learning, has made waves in the health care industry, with several prominent examples shown in ophthalmology. Despite the burgeoning reports on the development of new AI algorithms for detection and management of various eye diseases, few have reached the stage of regulatory approval for real-world implementation. To better enable real-world translation of AI systems, it is important to understand the demands, needs, and concerns of both health care professionals and patients, as providers and recipients of clinical care are impacted by these solutions. This review outlines the advantages and concerns of incorporating AI in ophthalmology care delivery, from both the providers' and patients' perspectives, and the key enablers for seamless transition to real-world implementation.
人工智能(AI),尤其是深度学习,在医疗保健行业掀起了浪潮,眼科领域有几个突出的例子。尽管有大量关于开发用于检测和管理各种眼部疾病的新 AI 算法的报告,但很少有达到监管批准用于实际实施的阶段。为了更好地实现 AI 系统的实际应用,了解医疗保健专业人员和患者的需求、需求和关注点非常重要,因为这些解决方案会影响到临床护理的提供者和接受者。本综述从提供者和患者的角度概述了将 AI 纳入眼科护理提供中的优势和关注点,以及实现无缝过渡到实际应用的关键推动因素。
Prog Retin Eye Res. 2021-5
Asia Pac J Ophthalmol (Phila). 2021-7-13
Cell Rep Med. 2023-7-18
Clin Exp Ophthalmol. 2018-9-30
Br J Ophthalmol. 2018-10-25
Asia Pac J Ophthalmol (Phila). 2019-4-18
Ophthalmol Ther. 2025-7-22
Medicina (Kaunas). 2025-2-28
Ther Adv Ophthalmol. 2024-12-4
Diagnostics (Basel). 2024-6-30
Front Ophthalmol (Lausanne). 2022-5-10
Adv Ophthalmol Pract Res. 2024-3-25